Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Deferasirox (Exjade®) as iron chelator in children
Hematologia 2011;2(1):83-87.
Abstract
Patients receiving recurrent blood transfusion as supportive therapy of chronic anemia in the
course of myelodysplastic syndromes, thalassemia and sickle-cell disease, are at risk of iron
accumulation. The clinical consequences of iron overload can be fatal. Therefore, the use of
a chelating agent is required to promote excretion of iron. At the present time, new iron chelators
that can be given orally are available. Deferasirox is a once-daily oral therapy for treating
transfusional iron overload, which improves patient compliance and quality of his life.
Hematologia 2011; 2, 1: 8387
Hematologia 2011; 2, 1: 8387
Keywords: chelation therapyiron overloaddeferasiroxdeferoxamine